Inmune Bio, Inc. current report, 16 July 2020

Full document

Business Context and Reporting Period

Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 16, 2020
Reporting Period: Event date of July 16, 2020.
Context: The Company, an emerging growth company, entered into a material definitive agreement to conduct a public offering of common stock.

Key Financial Metrics

This filing reports on a capital raise event rather than periodic operating results. Specific metrics include:

  • Shares Issued: 2,173,914 shares of common stock.
  • Public Offering Price: $10.00 per share.
  • Underwriting Price: $9.40 per share.
  • Over-Allotment Option: Up to an additional 326,086 shares.
  • Estimated Net Proceeds: Approximately $20 million (excluding over-allotment exercise).
  • Use of Proceeds: General corporate purposes, including research and development and clinical trials.

Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is an event-driven report.

Material Changes

The primary material change is the execution of an underwriting agreement with BTIG, LLC, representing the underwriters. This agreement facilitates the sale of the Company's common stock, increasing the Company's capital base pending the closing of the transaction.

Guidance, Outlook, and Risks

  • Outlook: The Company expects the Offering to close on July 20, 2020, subject to customary closing conditions.
  • Management Commentary: Proceeds will be utilized to support research and development activities, specifically clinical trials.
  • Risks and Contingencies: The closing is contingent upon the satisfaction of customary conditions. The Underwriting Agreement includes standard representations, warranties, termination provisions, and indemnification obligations.

Investor Verification Checklist

  • Verify the final closing date of the Offering (expected July 20, 2020).
  • Confirm whether the underwriters exercised the over-allotment option for an additional 326,086 shares.
  • Review the final prospectus supplement filed with the SEC for updated terms.
  • Monitor subsequent filings for the actual net proceeds received after deducting all expenses.